At the nexus of commercial success and non-obviousness
Dr. Gregory K. Bell recently testified in three successful challenges to abbreviated new drug applications (ANDA) on behalf of pharmaceutical manufacturers...
CRA experts prepare accounting, marketing and economic analyses relevant to Commercial Success, a secondary consideration in the determination of obviousness for patents. We provide clear and fact-supported testimony in all forums where the validity of patents is at issue, including in patent infringement litigation, PTAB IPRs, and in ITC Section 337 investigations. Our experts with deep experience in the pharmaceutical and life science sectors are particularly suited to addressing Commercial Success in ANDA/Hatch-Waxman litigation.
Engagements
- 01Evaluation of a blockbuster heart failure medicationOn behalf of a plaintiff for a blockbuster heart failure fixed-dose combination medication, CRA was retained to assess the commercial success of the product...View engagement
- 02Evaluation of an asthma medication with once-a-day dosingIn a Hatch-Waxman litigation involving a drug for asthma, CRA’s life sciences experts were asked to assess commercial success and its nexus to the patent. In...View engagement
- 03Evaluation of a diabetes treatmentCRA consultants supported a pharmaceutical company in its successful challenge of an ANDA filed by a generic manufacturer. The generic company sought to...View engagement